Canaccord analyst Edward Nash reiterated a Buy rating and $5.00 price target on Rani Therapeutics (NASDAQ: RANI).The analyst commented: "Rani ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments